Clinical Trials Browser

Interventional × ALT-803 × Breast × Clear all

NCT03175666 2025-02-21

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Phase 1/2 Withdrawn

Triple Negative Breast Neoplasms

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT03387085 2024-08-09

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Phase 1/2 Terminated

9 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT03127098 2024-08-06

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

Phase 1/2 Terminated

3 enrolled 6 charts

BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Thyroid Neoplasms

NCT04927884 2024-06-12

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Phase 1/2 Terminated

3 enrolled 9 charts

Advanced Triple Negative Breast Cancer